secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K/A
Filed at:   2023-07-14T23:59:59+00:00
Accession:  0001619856-23-000093
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou announces positive long-term follow-up from ANTLER Phase 1 of CB-010
----------------------------------------------------------------------------

- Positive long-term follow-up results from dose escalation portion of ANTLER Phase 1 trial.
- CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for relapsed/refractory B-NHL.
- Results announced July 13, 2023; this 8-K/A corrects an XBRL date error on the cover page.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000093/0001619856-23-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000093/crbu-20230713.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer